BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11057321)

  • 21. Single-agent paclitaxel for the treatment of breast cancer: an overview.
    Hortobagyi GN; Holmes FA
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):4-9. PubMed ID: 8629036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.
    Kondo K; Kobayashi M; Kojima H; Hirabayashi N; Kataoka M; Araki K; Matsui T; Takiyama W; Miyashita Y; Nakazato H; Nakao A; Sakamoto J
    Jpn J Clin Oncol; 2005 Jun; 35(6):332-7. PubMed ID: 15961435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Weekly paclitaxel infusion in patients with recurrent ovarian cancer--a pilot study].
    Kawagoe H; Kawata T; Nishio S; Shimomura T; Fujiyoshi K; Ishimatsu J; Tsunawaki A
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):151-4. PubMed ID: 12557722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Weekly paclitaxel administration in the adjuvant therapy of primary breast cancer].
    Takahashi H; Takahashi M; Taguchi K; Sasaki F; Todo S
    Gan To Kagaku Ryoho; 2003 May; 30(5):653-9. PubMed ID: 12795097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
    Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
    Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.
    Lee KS; Chung HC; Im SA; Park YH; Kim CS; Kim SB; Rha SY; Lee MY; Ro J
    Breast Cancer Res Treat; 2008 Mar; 108(2):241-50. PubMed ID: 17476588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.
    Toppmeyer D; Seidman AD; Pollak M; Russell C; Tkaczuk K; Verma S; Overmoyer B; Garg V; Ette E; Harding MW; Demetri GD
    Clin Cancer Res; 2002 Mar; 8(3):670-8. PubMed ID: 11895894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Complete response of gastric cancer with interaorticocaval lymph node recurrence to weekly administration of paclitaxel--a case report].
    Chou H; Shiomi A; Ogaki M; Takashina K; Kawakami S; Fujita Y
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):605-7. PubMed ID: 15114709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
    Ferrari AC; Chachoua A; Singh H; Rosenthal M; Taneja S; Bednar M; Mandeli J; Muggia F
    Cancer; 2001 Jun; 91(11):2039-45. PubMed ID: 11391583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Weekly paclitaxel in women with heavily pretreated metastatic breast cancer: a retrospective analysis of cases treated at the Chang Gung Memorial Hospital.
    Lu CH; Lin YC; Chang HK
    Chang Gung Med J; 2007; 30(1):33-40. PubMed ID: 17477027
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01).
    Sato K; Inoue K; Saito T; Kai T; Mihara H; Okubo K; Koh J; Mochizuki H; Tabei T;
    Jpn J Clin Oncol; 2003 Aug; 33(8):371-6. PubMed ID: 14523055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
    Borghaei H; Millenson M; Schilder R; Alden M; Rogatko A; Wang H; Padavic-Shaller K; Smith MR
    Cancer; 2004 Nov; 101(9):2034-41. PubMed ID: 15455357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Weekly administration regimen of paclitaxel (PTX) in patient with inoperable or recurrent gastric cancer].
    Kii T; Takiuchi H; Gotoh M; Kawabe S; Ohta S; Tanaka T; Kuwakado S; Nishitani H; Katsu K
    Gan To Kagaku Ryoho; 2006 May; 33(5):621-4. PubMed ID: 16685160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
    Rizvi NA; Riely GJ; Azzoli CG; Miller VA; Ng KK; Fiore J; Chia G; Brower M; Heelan R; Hawkins MJ; Kris MG
    J Clin Oncol; 2008 Feb; 26(4):639-43. PubMed ID: 18235124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.
    Penel N; Bui BN; Bay JO; Cupissol D; Ray-Coquard I; Piperno-Neumann S; Kerbrat P; Fournier C; Taieb S; Jimenez M; Isambert N; Peyrade F; Chevreau C; Bompas E; Brain EG; Blay JY
    J Clin Oncol; 2008 Nov; 26(32):5269-74. PubMed ID: 18809609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy.
    Brenner B; Ilson DH; Minsky BD; Bains MS; Tong W; Gonen M; Kelsen DP
    J Clin Oncol; 2004 Jan; 22(1):45-52. PubMed ID: 14701767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pilot study of weekly paclitaxel administration for patients with relapsed cervical cancer after heavy medication.
    Terauchi F; Nagashima T; Kobayashi Y; Yamamoto Y; Moritake T; Seiki T; Ogura H
    Gan To Kagaku Ryoho; 2005 May; 32(5):641-4. PubMed ID: 15918564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Phase I study of paclitaxel].
    Horikoshi N; Inoue K; Aiba K; Mukaiyama T; Ogihara A; Sumida T; Akatsuka Y; Besho A; Inamoto Y; Uchida T
    Gan To Kagaku Ryoho; 1994 Oct; 21(14):2407-14. PubMed ID: 7944484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Weekly Taxol (Paclitaxel) administration in the second-line treatment of breast cancer].
    Dank M
    Magy Onkol; 2002; 46(2):189-91. PubMed ID: 12202898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Evaluation of weekly paclitaxel and doxifluridine (5'-DFUR) combination therapy in patients with advanced or recurrent breast cancer].
    Okamoto Y; Tominaga T; Okuyama N; Sawada T; Kou Y
    Gan To Kagaku Ryoho; 2003 May; 30(5):661-7. PubMed ID: 12795098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.